Sept 23 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* XVIVO CAPITAL MARKETS DAY PRESENTS STRATEGIC FOCUS AREAS
FOR
2022-2026
* XVIVOS AMBITION IS TO REACH AN EBIT-MARGIN OF 20 % AND AN
EBITDA-MARGIN OF 30 % DURING STRATEGY PERIOD
* IN 2026, ABDOMINAL REVENUE IS EXPECTED TO BE OF EQUAL SIZE
AS
THORACIC REVENUE
* WILL CONTINUE TO BUILD ON ITS WORLD LEADING POSITION IN
LUNG
TRANSPLANTATION AND DEVELOP OFFERING TO COVER ALL FOUR MAJOR
ORGANS: LUNG, HEART, KIDNEY AND LIVER
Source text for Eikon: ID:nMFN7TQ4VQ
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))